Literature DB >> 23143695

The cardiovascular system in growth hormone excess and growth hormone deficiency.

G Lombardi1, C Di Somma, L F S Grasso, M C Savanelli, A Colao, R Pivonello.   

Abstract

The clinical conditions associated with GH excess and GH deficiency (GHD) are known to be associated with an increased risk for the cardiovascular morbidity and mortality, suggesting that either an excess or a deficiency in GH and/or IGF-I is deleterious for cardiovascular system. In patients with acromegaly, chronic GH and IGF-I excess commonly causes a specific cardiomyopathy characterized by a concentric cardiac hypertrophy associated with diastolic dysfunction and, in later stages, with systolic dysfunction ending in heart failure if GH/IGF-I excess is not controlled. Abnormalities of cardiac rhythm and anomalies of cardiac valves can also occur. Moreover, the increased prevalence of cardiovascular risk factors, such as hypertension, diabetes mellitus, and insulin resistance, as well as dyslipidemia, confer an increased risk for vascular atherosclerosis. Successful control of the disease is accompanied by a decrease of the cardiac mass and improvement of cardiac function and an improvement in cardiovascular risk factors. In patients with hypopituitarism, GHD has been considered the under- lying factor of the increased mortality when appropriate standard replacement of the pituitary hormones deficiencies is given. Either childhood-onset or adulthood-onset GHD are characterized by a cluster of abnormalities associated with an increased cardiovascular risk, including altered body composition, unfavorable lipid profile, insulin resistance, endothelial dysfunction and vascular atherosclerosis, a decrease in cardiac mass together with an impairment of systolic function mainly after exercise. Treatment with recombinant GH in patients with GHD is followed by an improvement of the cardiovascular risk factors and an increase in cardiac mass together with an improvement in cardiac performance. In conclusion, acromegaly and GHD are associated with an increased risk for cardiovascular morbidity and mortality, but the control of GH/IGF-I secretion reverses cardiovascular abnormalities and restores the normal life expectancy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23143695     DOI: 10.3275/8717

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  68 in total

Review 1.  Cardiovascular function in acromegaly.

Authors:  R N Clayton
Journal:  Endocr Rev       Date:  2003-06       Impact factor: 19.871

2.  Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy.

Authors:  A Colao; R Baldelli; P Marzullo; E Ferretti; D Ferone; P Gargiulo; M Petretta; G Tamburrano; G Lombardi; A Liuzzi
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

3.  The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues.

Authors:  M C De Martino; R S Auriemma; G Brevetti; G Vitale; V Schiano; M Galdiero; L Grasso; G Lombardi; A Colao; R Pivonello
Journal:  J Endocrinol Invest       Date:  2010-07-01       Impact factor: 4.256

4.  Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency.

Authors:  T A Elhadd; T A Abdu; J Oxtoby; G Kennedy; M McLaren; R Neary; J J Belch; R N Clayton
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

5.  Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency.

Authors:  A Colao; C di Somma; A Cuocolo; L Spinelli; N Tedesco; R Pivonello; D Bonaduce; M Salvatore; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

Review 6.  Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis.

Authors:  Patrick Maison; Anne-Isabelle Tropeano; Isabelle Macquin-Mavier; Andrea Giustina; Philippe Chanson
Journal:  J Clin Endocrinol Metab       Date:  2007-02-20       Impact factor: 5.958

7.  Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly.

Authors:  Marie-Lise Jaffrain-Rea; Giuseppe Minniti; Carlo Moroni; Vincenzo Esposito; Elisabetta Ferretti; Antonio Santoro; Tommaso Infusino; Guido Tamburrano; Giampaolo Cantore; Rosario Cassone
Journal:  Eur J Endocrinol       Date:  2003-02       Impact factor: 6.664

8.  Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults.

Authors:  V Markussis; S A Beshyah; C Fisher; P Sharp; A N Nicolaides; D G Johnston
Journal:  Lancet       Date:  1992-11-14       Impact factor: 79.321

Review 9.  Cardiovascular risk factors in hypopituitary GH-deficient adults.

Authors:  Johan Verhelst; Roger Abs
Journal:  Eur J Endocrinol       Date:  2009-08-14       Impact factor: 6.664

10.  Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study.

Authors:  R S Auriemma; R Pivonello; M Galdiero; M C De Martino; M De Leo; G Vitale; G Lombardi; A Colao
Journal:  J Endocrinol Invest       Date:  2008-11       Impact factor: 4.256

View more
  26 in total

Review 1.  Cardiovascular Disease in Acromegaly.

Authors:  Morali D Sharma; Anh V Nguyen; Spandana Brown; Richard J Robbins
Journal:  Methodist Debakey Cardiovasc J       Date:  2017 Apr-Jun

2.  Severe growth hormone deficiency and empty sella in obesity: a cross-sectional study.

Authors:  Carla Lubrano; Marta Tenuta; Daniela Costantini; Palma Specchia; Giuseppe Barbaro; Sabrina Basciani; Stefania Mariani; Alfredo Pontecorvi; Andrea Lenzi; Lucio Gnessi
Journal:  Endocrine       Date:  2015-01-23       Impact factor: 3.633

3.  Is treated hypopituitarism associated with increased left ventricular strains?-detailed analysis from the three-dimensional speckle-tracking echocardiographic MAGYAR-Path Study.

Authors:  Attila Nemes; Árpád Kormányos; Nándor Gyenes; Nóra Ambrus; Ágnes Horváth; Csaba Lengyel; Zsuzsanna Valkusz
Journal:  Quant Imaging Med Surg       Date:  2022-01

Review 4.  Mediterranean Diet and Obesity-related Disorders: What is the Evidence?

Authors:  Giovanna Muscogiuri; Ludovica Verde; Cem Sulu; Niki Katsiki; Maria Hassapidou; Evelyn Frias-Toral; Gabriela Cucalón; Agnieszka Pazderska; Volkan Demirhan Yumuk; Annamaria Colao; Luigi Barrea
Journal:  Curr Obes Rep       Date:  2022-09-30

5.  MRI Assessment of Cardiac Function and Morphology in Adult Patients With Growth Hormone Deficiency: A Systematic Review and Meta-Analysis.

Authors:  Fabio Bioletto; Nunzia Prencipe; Alessandro Maria Berton; Chiara Bona; Mirko Parasiliti-Caprino; Riccardo Faletti; Ezio Ghigo; Silvia Grottoli; Valentina Gasco
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-10       Impact factor: 6.055

Review 6.  Improving Quality of Life in Patients with Pituitary Tumours.

Authors:  Iris Crespo; Alicia Santos; Eugenia Resmini; Elena Valassi; Maria Antonia Martínez-Momblán; Susan M Webb
Journal:  Eur Endocrinol       Date:  2013-03-15

Review 7.  [Diagnostics and treatment of acromegaly : Necessity for targeted monitoring of comorbidities].

Authors:  S Petersenn; M Christ-Crain; M Droste; R Finke; J Flitsch; I Kreitschmann-Andermahr; A Luger; J Schopohl; G Stalla
Journal:  Internist (Berl)       Date:  2017-11       Impact factor: 0.743

8.  Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes.

Authors:  Maritza J Romero; Rudolf Lucas; Huijuan Dou; Supriya Sridhar; Istvan Czikora; Eby M Mosieri; Ferenc G Rick; Norman L Block; Subbaramiah Sridhar; David Fulton; Neal L Weintraub; Zsolt Bagi; Andrew V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-01       Impact factor: 11.205

9.  Association between Growth Differentiation Factor-15 and Risk of Cardiovascular Diseases in Patients with Adult Growth Hormone Deficiency.

Authors:  Xun Wu; Yunting Wang; Ziyu Ren; Linman Li; Wenjie Qian; Yue Chen; Wei Ren
Journal:  Int J Endocrinol       Date:  2021-08-06       Impact factor: 3.257

10.  LEAP-2/ghrelin interplay in adult growth hormone deficiency: Cause or consequence? A pilot study.

Authors:  Edoardo Vergani; Carmine Bruno; Cesare Gavotti; Luigi Simone Aversa; Maria Martire; Antonio Mancini; Diego Currò
Journal:  IUBMB Life       Date:  2021-05-28       Impact factor: 3.885

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.